Literature DB >> 9875428

Synthesis and properties of dextran-5-aminosalicylic acid ester as a potential colon-specific prodrug of 5-aminosalicylic acid.

Y J Jung1, J S Lee, H H Kim, Y T Kim, Y M Kim.   

Abstract

Dextran-5-aminosalicylic acid ester (dextran-5-ASA) was synthesized as a colon-specific prodrug of 5-aminosalicylic acid (5-ASA) which is active against inflammatory bowel diseases. Chemical stability of dextran-5-ASA in the bath of pH 1.2 or 6.8 was investigated at 37 degrees C for 6 hrs, and 5-ASA was not released on such conditions. Depolymerization (%) of dextran-5-ASA by dextranase with the degree of substitution (DS) of 18, 23, or 30 was 92, 62 or 45 in 8 hrs respectively, but was not affected by the MW of dextran (9,000, 40,600, 80,200 or 580,000). Distribution of 5-ASA in dextran, determined by gel filtration chromatography, appeared to be relatively uniform. Incubation of dextran-5-ASA (DS 18) in cecal contents of rats released 20% (28 g) and 35% (49 g) of 5-ASA in 8 hrs and 24 hrs, respectively, but no 5-ASA was liberated from small intestinal contents.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9875428     DOI: 10.1007/bf02974025

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  4 in total

Review 1.  Colonic drug delivery: prodrug approach.

Authors:  V R Sinha; R Kumria
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

2.  Synthesis and Characterization of 5-Aminosalicylic Acid Based Poly(anhydride-esters) by Solution Polymerization.

Authors:  Youngmi Kim; Kathryn E Uhrich
Journal:  J Polym Sci A Polym Chem       Date:  2010-12-15       Impact factor: 2.702

3.  Concise assembly of linear alpha(1-->6)-linked octamannan fluorescent probe.

Authors:  Mohammad S Aqueel; Vibha Pathak; Ashish K Pathak
Journal:  Tetrahedron Lett       Date:  2008-12-08       Impact factor: 2.415

4.  Conjugation of metronidazole with dextran: a potential pharmaceutical strategy to control colonic distribution of the anti-amebic drug susceptible to metabolism by colonic microbes.

Authors:  Wooseong Kim; Yejin Yang; Dohoon Kim; Seongkeun Jeong; Jin-Wook Yoo; Jeong-Hyun Yoon; Yunjin Jung
Journal:  Drug Des Devel Ther       Date:  2017-02-14       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.